$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000142545022000093 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$34.95M	$32.93M	$23.42M
YoY Change	39.36%	23.35%	9.11%
Cost Of Revenue	$9.061M	$7.947M	$4.851M
YoY Change	38.87%	27.11%	-5.57%
Gross Profit	$25.89M	$24.98M	$18.57M
YoY Change	39.53%	22.2%	13.73%
Gross Profit Margin	74.07%	75.87%	79.28%
Selling, General & Admin	$27.04M	$26.98M	$22.93M
YoY Change	29.38%	22.82%	9.22%
% of Gross Profit	104.43%	107.99%	123.48%
Research & Development	$2.206M	$1.747M	$2.027M
YoY Change	69.43%	31.85%	54.97%
% of Gross Profit	8.52%	6.99%	10.92%
Depreciation & Amortization	$3.287M	$3.331M	$2.961M
YoY Change	20.71%	27.77%	16.62%
% of Gross Profit	12.7%	13.33%	15.95%
Operating Expenses	$32.85M	$28.72M	$24.95M
YoY Change	47.99%	23.34%	11.9%
Operating Profit	-$6.961M	-$3.743M	-$6.386M
YoY Change	91.03%	31.52%	6.91%
Interest Expense	$22.30M	$3.798M	-$3.136M
YoY Change	2411.49%	-341.76%	-35.74%
% of Operating Profit
Other Income/Expense, Net	$21.36M	$2.971M	-$3.031M
YoY Change	1749.09%	-348.41%	-35.76%
Pretax Income	$14.40M	-$772.0K	-$9.417M
YoY Change	-678.38%	-80.9%	-11.92%
Income Tax	-$4.143M	-$439.0K	-$317.0K
% Of Pretax Income	-28.78%
Net Earnings	$18.54M	-$333.0K	-$9.100M
YoY Change	-943.83%	-91.13%	-12.32%
Net Earnings / Revenue	53.04%	-1.01%	-38.86%
Basic Earnings Per Share	$0.88	-$0.02	-$0.47
Diluted Earnings Per Share	$0.87	-$0.02	-$0.47
COMMON SHARES
Basic Shares Outstanding	20.28M shares	19.79M shares	19.37M shares
Diluted Shares Outstanding	21.30M shares	19.79M shares	19.37M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$120.1M	$51.16M	$45.03M
YoY Change	108.26%	-22.31%	-41.22%
Cash & Equivalents	$36.87M	$37.20M	$17.96M
Short-Term Investments
Other Short-Term Assets	$4.200M	$4.069M	$4.411M
YoY Change	2.12%	5.91%	33.67%
Inventory	$74.04M	$67.48M	$64.08M
Prepaid Expenses
Receivables	$26.18M	$25.43M	$17.91M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$224.6M	$148.1M	$131.4M
YoY Change	65.78%	1.9%	-13.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$36.31M	$36.60M	$31.07M
YoY Change	26.16%	29.6%	9.62%
Goodwill	$88.04M	$71.71M	$70.99M
YoY Change	24.9%	2.94%	3.69%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$205.5M	$182.8M	$169.6M
YoY Change	22.22%	12.65%	5.11%
TOTAL ASSETS
Total Short-Term Assets	$224.6M	$148.1M	$131.4M
Total Long-Term Assets	$205.5M	$182.8M	$169.6M
Total Assets	$430.1M	$330.9M	$301.0M
YoY Change	41.65%	7.57%	-3.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.88M	$14.59M	$14.58M
YoY Change	21.28%	43.87%	21.39%
Accrued Expenses	$6.323M	$6.087M	$4.433M
YoY Change	35.83%	7.72%	-56.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$143.0K	$141.0K	$139.0K
YoY Change	5.15%	5.22%	5.3%
Total Short-Term Liabilities	$28.75M	$31.21M	$34.33M
YoY Change	2.6%	2.91%	-6.25%
LONG-TERM LIABILITIES
Long-Term Debt	$799.0K	$31.84M	$872.0K
YoY Change	-15.18%	3158.55%	-13.75%
Other Long-Term Liabilities	$440.0K	$300.0K	$241.0K
YoY Change	37.5%	2.74%	-23.49%
Total Long-Term Liabilities	$17.98M	$72.51M	$51.62M
YoY Change	-66.99%	30.12%	-5.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.75M	$31.21M	$34.33M
Total Long-Term Liabilities	$17.98M	$72.51M	$51.62M
Total Liabilities	$46.72M	$103.7M	$85.95M
YoY Change	-43.35%	20.53%	-5.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$168.9M	-$187.5M	-$187.1M
YoY Change	-5.15%	6.57%	8.7%
Common Stock	$6.000K	$5.000K	$5.000K
YoY Change	20.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$383.3M	$227.2M	$215.0M
YoY Change
Total Liabilities & Shareholders Equity	$430.1M	$330.9M	$301.0M
YoY Change	41.65%	7.57%	-3.94%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$18.54M	-$333.0K	-$9.100M
YoY Change	-943.83%	-91.13%	-12.32%
Depreciation, Depletion And Amortization	$3.287M	$3.331M	$2.961M
YoY Change	20.71%	27.77%	16.62%
Cash From Operating Activities	-$6.058M	-$8.170M	-$4.197M
YoY Change	546.53%	-8.93%	119.16%
INVESTING ACTIVITIES
Capital Expenditures	-$1.089M	-$5.268M	$4.197M
YoY Change	-84.54%	205.92%	52.67%
Acquisitions
YoY Change
Other Investing Activities	-$102.8M	$4.740M	$18.50M
YoY Change	-2670.75%
Cash From Investing Activities	-$103.9M	-$528.0K	$14.30M
YoY Change	3313.9%	-69.34%	-355.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	108.3M	27.77M	-$33.00K
YoY Change	257680.95%	-86893.75%	-210.0%
NET CHANGE
Cash From Operating Activities	-6.058M	-8.170M	-$4.197M
Cash From Investing Activities	-103.9M	-528.0K	$14.30M
Cash From Financing Activities	108.3M	27.77M	-$33.00K
Net Change In Cash	-1.709M	19.08M	$10.31M
YoY Change	-56.61%	-277.86%	-240.58%
FREE CASH FLOW
Cash From Operating Activities	-$6.058M	-$8.170M	-$4.197M
Capital Expenditures	-$1.089M	-$5.268M	$4.197M
Free Cash Flow	-$4.969M	-$2.902M	-$8.394M
YoY Change	-181.37%	-59.97%	79.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.orthopediatrics.com/20220630#AssetsNoncurrentExcludingPropertyPlantAndEquipment
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.orthopediatrics.com/20220630#AssetsNoncurrentExcludingPropertyPlantAndEquipment
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38242
	dei	Entity Registrant Name EntityRegistrantName	OrthoPediatrics Corp
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1761833
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2850 Frontier Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warsaw
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46582
	dei	City Area Code CityAreaCode	574
	dei	Local Phone Number LocalPhoneNumber	268-6379
	dei	Security12b Title Security12bTitle	Common Stock, $0.00025 par value per share
	dei	Trading Symbol TradingSymbol	KIDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20278189	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37198000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7641000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1357000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1365000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	13963000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	45902000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	412000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	347000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25434000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17942000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	67484000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	57569000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2712000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3229000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	148148000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	133648000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36601000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28515000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	58777000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55494000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	71707000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	72349000	usd
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	15708000	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	14268000	usd
CY2022Q2	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	146192000	usd
CY2021Q4	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	142111000	usd
CY2022Q2	us-gaap	Assets Assets	330941000	usd
CY2021Q4	us-gaap	Assets Assets	304274000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	14591000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9325000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6087000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5351000	usd
CY2022Q2	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	141000	usd
CY2021Q4	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	137000	usd
CY2022Q2	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	7445000	usd
CY2021Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	12862000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2949000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2040000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	31213000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29715000	usd
CY2022Q2	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	31836000	usd
CY2021Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	907000	usd
CY2022Q2	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	7626000	usd
CY2021Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	14309000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	26470000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	28910000	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6280000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4771000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	300000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	293000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	72512000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	49190000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	103725000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	78905000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20238870	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20238870	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19677214	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19677214	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418354000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	394899000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-187459000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178026000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3684000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8491000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	227216000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	225369000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	330941000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	304274000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32928000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26695000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56345000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48157000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7947000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6252000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12798000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11389000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	24981000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	20443000	usd
	us-gaap	Gross Profit GrossProfit	43547000	usd
	us-gaap	Gross Profit GrossProfit	36768000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12431000	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10876000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22189000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19825000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14546000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11088000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27713000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23129000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1747000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1325000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3774000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2633000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	28724000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	23289000	usd
	us-gaap	Operating Expenses OperatingExpenses	53676000	usd
	us-gaap	Operating Expenses OperatingExpenses	45587000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3743000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2846000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10129000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8819000	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1212000	usd
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-581000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1777000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1309000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5010000	usd
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	990000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2440000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5140000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-827000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	375000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-723000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	535000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2971000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1196000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-60000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5914000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-772000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4042000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10189000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14733000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-439000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-286000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-756000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-598000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-333000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9433000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14135000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19792286	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19792286	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19275779	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19275779	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19693216	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19693216	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19263506	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19263506	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-333000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9433000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14135000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9299000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1867000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-11497000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1631000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-125000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-70000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-678000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-194000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9424000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1797000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-12175000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1825000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9757000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1959000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21608000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15960000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	225369000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-9100000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2751000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1526000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	215044000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-333000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9424000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1770000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9707000	usd
CY2022Q2	kids	Stock Issued During Period Value Anniversary Installment Payment StockIssuedDuringPeriodValueAnniversaryInstallmentPayment	10410000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	227216000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	234768000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-10379000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3622000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1316000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	222145000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1797000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1415000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	221601000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9433000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14135000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6292000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5147000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3296000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2731000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2440000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5140000	usd
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1545000	usd
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1212000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	756000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	602000	usd
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	6614000	usd
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	1781000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10905000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3297000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-557000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-106000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5298000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	191000	usd
	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	0	usd
	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	6342000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1133000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1080000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	340000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	341000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12367000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10891000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	8360000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	31600000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2858000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9465000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4474000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13775000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7332000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	31000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	3234000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	62000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	67000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	64000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27741000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	400000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29549000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18196000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9006000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30132000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38555000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11936000	usd
	us-gaap	Interest Paid Net InterestPaidNet	60000	usd
	us-gaap	Interest Paid Net InterestPaidNet	29000	usd
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	-130000	usd
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	330000	usd
	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS<div style="padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediPlates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Cannulated Screws, PediFlex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">nail, PediNail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Spine, BandLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Pediatric Nailing Platform \| Femur, Orthex, QuickPack</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> and ApiFix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div style="padding-right:8pt"><span><br/></span></div><div style="padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 560,000 children. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3,300,000 opportunity globally, including over $1,500,000 in the United States.</span></div><div style="padding-right:5pt"><span><br/></span></div><div style="padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">Our largest investor is Squadron, a private investment firm based in Granby, Connecticut. </span></div>A novel strain of the coronavirus disease was first identified in Wuhan, China in December 2019, and the related outbreak was subsequently declared a pandemic by the World Health Organization and a national emergency by the President of the United States. As a result of the pandemic, we have experienced significant business disruption. For example, in order to meet the demand for COVID-19-related hospitalizations, various governments, governmental agencies and hospital administrators required certain hospitals to postpone some elective procedures. In addition, elective procedures are also being delayed in some cases as hospitals continue to struggle with adequate staffing levels. As a majority of our products are utilized in elective surgeries or procedures, the deferrals of such surgeries and procedures have had, and may continue to have, a significant negative impact on our business and results of operations. Despite the impact COVID-19 has had on our business, we continued to invest in research and development, invest in our people, and take steps to position ourselves for long-term success. We continue to train and educate our sales team and our surgeons on our products. We have continued to focus on developing innovative solutions, acquired multiple enabling technologies, invested in both new and existing partnerships and continued to deploy additional consigned instrument and implant sets in furtherance of our strategy. The extent to which COVID-19 may continue to negatively impact the Company's consolidated financial position, results of operations or cash flows is uncertain and will be closely monitored.
CY2022Q2	kids	Cumulative Children Impacted Count CumulativeChildrenImpactedCount	560000	children
CY2022Q2	kids	Estimated Market Portion Opportunities EstimatedMarketPortionOpportunities	3300000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-187459000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178026000	usd
	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesPreparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.
CY2022Q2	us-gaap	Escrow Deposit EscrowDeposit	1250000	usd
CY2021Q4	us-gaap	Escrow Deposit EscrowDeposit	1250000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	eur
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2021Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2021Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingunit
CY2022Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2021Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022Q2	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1092000	usd
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1545000	usd
CY2021Q2	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	569000	usd
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1212000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5010000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2440000	usd
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	990000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5140000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q4	us-gaap	Goodwill Goodwill	72349000	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	5157000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-5799000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	71707000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	70507000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11730000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	58777000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	65014000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9520000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.04
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55494000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5010000	usd
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	990000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2440000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5140000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	31977000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-598000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.074
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	1044000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-756000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	22671000	usd
CY2021Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	176000	usd
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation	23920000	usd
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	1062000	usd
CY2018Q4	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	9736000	usd
CY2018Q4	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease	22430000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-333000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9433000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14135000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19792286	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19792286	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19275779	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19275779	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19693216	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19693216	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19263506	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19263506	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	438391	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	392449	shares
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32928000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26695000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56345000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48157000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32928000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26695000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56345000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48157000	usd
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	300000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	302000	usd
CY2022Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1140000	usd

Files In Submission

Name	View Source	Status
0001425450-22-000093-index-headers.html	Edgar Link	pending
0001425450-22-000093-index.html	Edgar Link	pending
0001425450-22-000093.txt	Edgar Link	pending
0001425450-22-000093-xbrl.zip	Edgar Link	pending
exhibit311-ceocertificatio.htm	Edgar Link	pending
exhibit312-cfocertificatio.htm	Edgar Link	pending
exhibit321-ceocertificatio.htm	Edgar Link	pending
exhibit322-cfocertificatio.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kids-20220630.htm	Edgar Link	pending
kids-20220630.xsd	Edgar Link	pending
kids-20220630_cal.xml	Edgar Link	unprocessable
kids-20220630_def.xml	Edgar Link	unprocessable
kids-20220630_htm.xml	Edgar Link	completed
kids-20220630_lab.xml	Edgar Link	unprocessable
kids-20220630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2022 Q3 Form 10-Q Financial Statement

#000142545022000093 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2022 Q3 Form 10-Q Financial Statement

#000142545022000093 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids